Wutah pendapatan taunan sajrone rolas wulan kepungkur: OncoCyte Corporation (OCX)

Tandha merek OncoCyte Corporation (OCX)

OncoCyte Corporation maintains its position in molecular diagnostics through the accuracy of hospital-based tests, resisting pressure from large laboratory behemoths. The TTM annual sales growth rate demonstrates a correlation between revenue and personnel costs, with the current mark equal to 0.00. Optimized reagent supplies eliminate shortages, and profitability is rising as services are integrated into medical standards.

Wutah dodolan YoY sajrone rolas wulan kepungkur OncoCyte Inc (OCX): kanggo periode 11.02.2024 - 20.02.2024

Ringkesan rincian data analitis OncoCyte Inc (OCX)

- nilai saham lan prakiraan konsensus rega:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:OCX - OncoCyte Corporation
Produk seri OncoCyte Corp.

The development of VitaGraft diagnostic tests through partnerships with transplant centers directly determines the incoming cash flow dynamics of OncoCyte Corporation (OCX). By analyzing year-over-year sales volatility over a rolling 12-month period, an investor assesses revenue growth rates without the influence of seasonality, yet must consider that sharp spikes on the chart may mask liquidity shortages and create risks for the asset's capitalization.